Psychedelic Investor Pulse Survey Results (Summer 2022) Post published:July 19, 2022 Post category:Uncategorized
George Tziras to Succeed Peter Rands as Small Pharma Chief Executive Officer Post published:July 18, 2022 Post category:Press Release
Small Pharma Reports Fiscal First Quarter 2023 Highlights Post published:July 17, 2022 Post category:Press Release
FILAMENT HEALTH ANNOUNCES CLOSING OF $2,500,080 PRIVATE PLACEMENT Post published:July 16, 2022 Post category:Press Release
Numinus Wellness Inc. Reports Q3 2022 Results Post published:July 16, 2022 Post category:Press Release
Psychedelic Bulletin #111 – Psychedelics on Netflix; House Adopts 2 Psychedelic Research Amendments; Taking the Magic Out of Magic Mushrooms? Post published:July 15, 2022 Post category:Psychedelic Bulletin
Silo Pharma Announces Positive Results in Subcutaneous Delivery of its Novel Liposomes to Treat Arthritic Patients Post published:July 15, 2022 Post category:Press Release
Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And Research Centre Post published:July 15, 2022 Post category:Press Release
PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson’s Disease and Motor Disorders Post published:July 13, 2022 Post category:Press Release
FILAMENT HEALTH ISSUED THIRD PATENT BY UNITED STATES PATENT AND TRADEMARK OFFICE Post published:July 13, 2022 Post category:Press Release